AACP
LGND icon

Advantage Alpha Capital Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Advantage Alpha Capital Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,823
Closed -$207K – 138
2025
Q2 		$207K Buy
+1,823
New +$195K 0.06% 114

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advantage Alpha Capital Partners's LGND Position: Q3 2025 in Review

Advantage Alpha Capital Partners sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 1,823 shares — an estimated $207K sold.

Advantage Alpha Capital Partners first reported a position in LGND in Q2 2025 and held it in 1 quarter. The position peaked at $207K in Q2 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Advantage Alpha Capital Partners reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 1,823 Ligand Pharmaceuticals shares in Q3 2025, an estimated $207K.
  • Advantage Alpha Capital Partners first reported a position in Ligand Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Ligand Pharmaceuticals position peaked at $207K in Q2 2025.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.